Boosting daily requirement of vitamin C may be helpful in curbing the development of leukemia -- a deadly blood cancer, a study has found.
Previous studies have shown that people with lower levels of ascorbate (vitamin C) are at an increased cancer risk but the reasons were not fully understood.
The new study, published in the journal Nature, showed that stem cells soak up unusually high levels of vitamin C, which then regulates the cell function and suppresses the development of leukemia.
"Stem cells use ascorbate to regulate the abundance of certain chemical modifications on DNA, which are part of the epigenome," explained Michalis Agathocleous, from University of Texas Southwestern Medical Centre.
"The epigenome is a set of mechanisms inside a cell that regulates which genes turn on and turn off. So when stem cells don't receive enough vitamin C, the epigenome can become damaged in a way that increases stem cell function but also increases the risk of leukemia," Agathocleous added.
This increased risk is partly tied to how ascorbate affects an enzyme known as Tet2. Mutations that inactivate Tet2 are an early step in the formation of leukemia.
Ascorbate depletion can limit Tet2 function in tissues in a way that increases the risk of leukemia, the researchers explained.
Importantly, the findings have implications for older patients with a common precancerous condition known as clonal hematopoiesis, which puts patients at a higher risk of developing leukemia and other diseases.
"One of the most common mutations in patients with clonal hematopoiesis is a loss of one copy of Tet2. Our results suggest patients with clonal hematopoiesis and a Tet2 mutation should be particularly careful to get 100 per cent of their daily Vitamin C requirement," said Sean Morrison, Director at the varsity.
"Because these patients only have one good copy of Tet2 left, they need to maximise the residual Tet2 tumour-suppressor activity to protect themselves from cancer," Morrison noted.
--IANS
rt/amit/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
